Oncolytics Biotech Inc. Reports Completion of Initial Safety Phase Enrollment for GOBLET Trials New Pancreatic Cancer Cohort - Marketscreener.com
| ONC Stock | CAD 1.23 0.02 1.60% |
About 62% of Oncolytics Biotech's investor base is looking to short. The analysis of the overall investor sentiment regarding Oncolytics Biotech suggests that many traders are alarmed. Oncolytics Biotech's investing sentiment overview a quick insight into current market opportunities from investing in Oncolytics Biotech. Many technical investors use Oncolytics Biotech stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Oncolytics |
Oncolytics Biotech Inc. Reports Completion of Initial Safety Phase Enrollment for GOBLET Trials New Pancreatic Cancer Cohort Marketscreener.com
Read at news.google.com
 |
Oncolytics Biotech Fundamental Analysis
We analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Oncolytics Biotech is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Oncolytics Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oncolytics Biotech stock to make a market-neutral strategy. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics with similar companies.
Peers
Oncolytics Biotech Related Equities
| FFH-PG | Fairfax Fin | 0.69 | ||||
| FFH-PI | Fairfax Financial | 0.18 | ||||
| FFH-PH | Fairfax Financial | 0.05 | ||||
| FFH-PC | Fairfax Fin | 0.04 | ||||
| FFH-PE | Fairfax Financial | 0.09 | ||||
| FFH-PF | Fairfax Financial | 0.43 | ||||
| PIC-A | Premium Income | 0.63 | ||||
| FFH | Fairfax Financial | 0.64 | ||||
| FFH-PK | Fairfax Financial | 1.12 | ||||
| ELF | E L | 6.62 |
Check out Oncolytics Biotech Hype Analysis, Oncolytics Biotech Correlation and Oncolytics Biotech Performance. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.